iRhythm reported second quarter results that beat analyst expectations, with revenue of $224.2 million versus estimates of $219.2 million, a 20.1% year-on-year increase, and adjusted EPS of $0.58 versus estimates of $0.04. The company also raised its full-year revenue guidance to $885 million at the midpoint from $880 million. During the earnings call, analysts focused on the VitalConnect acquisition, with CEO Quentin Blackford explaining that a multi-product approach is needed to cover the full spectrum of physician and patient preferences in the MCT market, and CFO Dan Wilson estimating share issuance would be less than 1.5% dilution. Other questions covered the sustainability of EBITDA margin gains, direct-to-patient marketing efforts, and potential cannibalization of iRhythm's own MCT development.
iRhythm Technologies IncQ2 beat and raised guidance
Acquisition discussed, dilution estimated
